​

Funding Round

Series D - ORIC Pharmaceuticals

Series D - ORIC Pharmaceuticals

Investment Firm

Overview

ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.

Announced Date

Aug 09, 2019

Funding Type

Series D

Highlights

Location

United States, North America

Social

Investor Lead

Invus

Invus

Invus is a early_stage_venture and late_stage_venture and post_ipo and private_equity and venture firm.

ArrowMark Partners

ArrowMark Partners

ArrowMark Partners is a debt and early_stage_venture and late_stage_venture and private_equity firm.

Participant Investors

14

Investor Name
Participant InvestorTaiho Ventures
Participant InvestorThe Column Group
Participant InvestorInvus
Participant InvestorCorrelation Ventures
Participant InvestorFidelity

Round Details and Background

ORIC Pharmaceuticals raised $55000000 on 2019-08-09 in Series D

ORIC Pharmaceuticals is a biopharmaceutical company that develops treatments that target the causes of therapeutic resistance.

Company Funding History

7

Announcment DateTransaction NameNumber Of InvestorsLead InvestorMoney Raised
Jun 26, 2023
Post-IPO Equity - ORIC Pharmaceuticals
6-85.0M
Jan 30, 2024
Post-IPO Equity - ORIC Pharmaceuticals
-125.0M
Nov 01, 2014
Series A - ORIC Pharmaceuticals
1-15.0M
Dec 02, 2015
Series B - ORIC Pharmaceuticals
6-53.0M

Recent Activity

There is no recent news or activity for this profile.